Humulin S (Soluble)

Humulin S (Soluble) is a brand‑name injectable solution that contains insulin human at a concentration of 100 U/mL. It is a prescription‑only product marketed in the European Union and administered subcutaneously. As a synthetic analogue of endogenous human insulin, Humulin S provides rapid‑acting glucose‑lowering activity for patients with diabetes mellitus. The formulation is supplied in vials or cartridges for use with appropriate syringes or pens in clinical practice.

Humulin S is indicated for the control of blood glucose in patients who require insulin replacement, including both type 1 and type 2 diabetes mellitus, as well as specific acute metabolic situations commonly. - Initiation of insulin therapy in newly diagnosed type 1 diabetes. - Supplemental insulin for type 2 diabetes patients inadequately controlled on oral agents. - Adjustment of basal insulin during pregnancy (category B) under medical supervision. - Adjunctive treatment of diabetic ketoacidosis when combined with intravenous insulin. - Perioperative glucose management in surgical patients with diabetes.

Adverse reactions to Humulin S may vary in frequency and severity; they are generally related to its pharmacologic action or formulation.

Common: - Mild hypoglycemia, characterized by sweating, tremor, or dizziness. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy presenting as localized fat loss or accumulation. - Transient weight gain due to fluid retention. - Transient visual disturbances such as blurred vision. - Mild nausea or abdominal discomfort.

Serious: - Severe hypoglycemia with loss of consciousness or seizures. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Hypersensitivity leading to eosinophilia or fever. - Persistent edema or heart failure exacerbation. - Insulin antibody formation that may alter drug efficacy.

When prescribing Humulin S, clinicians should evaluate patient-specific factors and monitor for conditions that could increase risk of adverse outcomes. - Assess renal or hepatic impairment, as reduced clearance may prolong insulin action. - Review history of hypoglycemia unawareness before initiating therapy. - Adjust dose during pregnancy, lactation, or in elderly patients. - Monitor for signs of infection or inflammation at injection sites. - Caution in patients with cardiovascular disease or heart failure due to fluid retention risk. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Consider temporary dose reduction during periods of reduced food intake or increased physical activity.

Humulin S may interact with other medications or substances that affect glucose metabolism, insulin absorption, or cardiovascular status.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - High‑dose beta‑blockers that mask hypoglycemia symptoms. - MAO‑inhibitors combined with sympathomimetic agents that can cause unpredictable glucose changes.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise blood glucose and require insulin dose changes. - Diuretics, especially thiazides, that can affect electrolyte balance and glucose control. - Alcohol consumption, which can potentiate hypoglycemia after insulin administration.